Physician profile
William Blau
NPI 1326084757
$3,022.89
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $121 · 2021: $258 · 2022: $351 · 2023: $221 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $558.42 | 2019-2024 | Xarelto |
| Amgen INC. | $453.76 | 2019-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $299.49 | 2019 | |
| Amarin Pharma, INC. | $295.13 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $205.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.30 | 2019-2020 | |
| Astellas Pharma US INC | $157.29 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $147.55 | 2019 | |
| Heartflow, INC. | $131.43 | 2023 | Ffrct |
| Merck Sharp & Dohme LLC | $128.34 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $81.76 | 2019-2021 | |
| Edwards Lifesciences Corporation | $68.93 | 2019 | |
| Pfizer INC. | $68.14 | 2019 | |
| Glaxosmithkline, LLC. | $41.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.56 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.22 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $27.54 | 2019-2021 | |
| Daiichi Sankyo INC. | $21.87 | 2019 | |
| Sanofi Pasteur INC. | $21.53 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $16.74 | 2019 | |
| Biogen, INC. | $16.49 | 2020 | |
| Novo Nordisk INC | $15.09 | 2019 | |
| Promius Pharma LLC | $13.29 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.82 | 2019 | |
| Allergan, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Blau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.